

©Copyright: the Author(s), 2025
Licensee PAGEPress, Italy

Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after checkpoint inhibitor treatment: a case report

Carlotta Bertolina,¹ Marinella Bertolotti,¹ Claudia Leporati,² Antonina Maria De Angelis,³ Sara Delfanti,³ Luigi Cerbone,³ Marco Ghiglione,⁴ Federica Grosso³

¹Research Training Innovation Infrastructure, Research and Innovation Department; ²Dermatology Unit; ³Mesothelioma, Melanoma and Rare Cancers Unit; ⁴Plastic and Reconstructive Surgery, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

Abstract

Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFi, MEKi), given as second-line therapy after failure of immunotherapy, who achieved a complete and durable response lasting for over 5 years. Significant progress has been achieved in the treatment of advanced melanoma with immune checkpoint inhibitors (ICIs) and targeted therapies using BRAFi and MEKi. While these treatments improve survival, they also pose risks of severe toxicities. Notably, when targeted therapy follows immunotherapy, immune-mediated toxicities may emerge months later due to tumor microenvironment modulation. Despite these risks, both approaches offer a durable response in eligible patients. Further understanding is needed to determine how prior immunotherapy may influence subsequent toxicity risks of target therapy. Understanding these factors could optimize treatment strategies and improve patient outcomes.

Key words: melanoma; targeted therapy; immune checkpoint inhibitors; adverse events; complete response.

Correspondence: Carlotta Bertolina, Research Training Innovation Infrastructure, Research and Innovation Department, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. E-mail: carlotta.bertolina@ospedale.al.it

Introduction

Melanoma represents one of the most common and lethal skin cancers, with an increasing incidence globally.¹ Over the past decade, significant progress has been made in improving survival rates, particularly among advanced melanoma patients. Immunotherapy involving immune checkpoint inhibitors (ICIs) has been approved as a single agent for the treatment of metastatic or unresectable melanoma. Among ICIs, pembrolizumab and nivolumab (PD-1) are commonly used in the treatment of metastatic melanoma. These agents can also be combined with ipilimumab, a distinct immune checkpoint inhibitor targeting CTLA-4.² In addition to immunotherapy, targeted therapy using BRAF and MEK inhibitors (BRAFi, MEKi) has recently shown promise in enhancing survival in patients with advanced cutaneous melanoma. In patients with *BRAF* mutations, inhibitors such as vemurafenib and dabrafenib have been approved for both single-agent and combination administration with MEKi, including cobimetinib and trametinib, respectively.³ Of more recent approval, the association of new BRAFi and MEKi agents, encorafenib and binimetinib, has been shown to provide an improvement in progression-free survival in patients with metastatic melanoma and a *BRAF* mutation.⁴ Despite promising results in several studies, these treatments are associated with various toxicities and side effects, which can sometimes be severe.⁵ Here, we report a case of a patient who developed both skin and ocular toxicities after switching from immunotherapy to targeted therapy.

Case Report

A 37-year-old woman was diagnosed with melanoma in the lymph node region after excision of a massive congenital nevus on the left upper arm. The patient underwent surgical removal of left axillary lymphadenopathy, which revealed melanoma positivity in 49/52 lymph nodes. Adjuvant targeted therapy with vemurafenib, a BRAFi, was initiated and continued from 2011 to 2014. During this period, she also underwent a left mastectomy due to locoregional recurrence. Given her desire for fertility preservation, it was agreed to discontinue the treatment.

In 2015, a PET scan detected pleural recurrence at the costovertebral region, requiring removal of chest wall nodules. First-line ICI therapy with nivolumab was started, for which the patient completed 55 cycles by 2018. While a total body CT scan performed in 2017 showed lesion reduction, subsequent disease progression to left retroperitoneal and supraclavicular lymph nodes was clearly evidenced by July 2018 (Figure 1).

This led us to initiate treatment with a second-line target therapy using dabrafenib, another BRAFi, in combination with the MEKi trametinib. However, 10 days into the therapy, the patient was urgently admitted to the hospital with hyperthermia and abdominal pain, requiring temporary discontinuation of treatment until resolution. Upon treatment resumption one month later, the patient developed a diffuse, nonpruritic maculopapular rash on her lower and upper extremities, along with fever, requiring oral steroid and

Case Report

antihistamine medication, which led to symptom resolution. Upon resumption of full therapy, a total body CT scan performed in November 2018 showed a complete response in left retroperitoneal and supraclavicular lymph nodes.

In January 2019, further therapy discontinuation became necessary due to diffuse arthralgias, lower extremity cramps, and fever, all of which improved after administration of prednisone (25 mg). On hematochemical examination, G2 leuko-neutropenia (white blood cells [WBC]: 2450/ μ L, neutrophils 1850/ μ L) was also observed.

In May 2019, targeted therapy was restarted, followed by total body CT findings indicating stability of retroperitoneal lymphadenopathy and left costovertebral lesions (Figure 2).

Three months later, the patient developed a cutaneous leg rash and fever, prompting discontinuation of the therapy and steroid administration, which resulted in a good response (Figure 3). Despite reducing the dosage, recurrent fever and further complications led us to decide to switch therapy to encorafenib and binimetinib, BRAFi and MEKi, respectively. A subsequent CT scan showed partial/complete response in the left costovertebral region lesion, resolution of left axillary and left parasternal lesions, and stable retroperitoneal lymphadenopathy of upper limit size.

The patient then sought an ophthalmologic consultation due to discomfort in the left eye and a decrease in visual acuity. Cystoid macular edema with a modest vascular tortuosity was found, for which fluoroangiography with indocyanine green and discontinuation of binimetinib were recommended. We also decided to discontinue encorafenib due to concerns that the ocular pathology may be related to BRAF inhibition. About three months later, the patient was diagnosed with posterior uveitis in the left eye, for

which an Ozurdex[®] injection was administered. Considering the negative findings for recurrence of oncologic disease and worsening uveitis, we decided to proceed with treatments for left eye issues while continuing a rigorous oncologic follow-up. A total body CT scan performed in November 2020 revealed no signs of supra- or sub-diaphragmatic secondary lesions, whereas a subsequent eye consultation indicated complete reabsorption of the macular edema in her left eye. On fluoroangiography, peripheral inflammatory foci in the left eye were stable, with vasculitis and papillary hyperfluorescence regression.

Currently, the patient remains disease-free, with ongoing oncologic follow-up.

Discussion

Here we report the case of a woman suffering from metastatic melanoma who experienced significant ocular and skin toxicities during BRAFi and MEKi therapy, administered as a second-line treatment after the failure of immunotherapy, resulting in a complete response lasting over five years.

To better understand the hypothesis behind such a significant response despite the observed toxicities, it is essential to first review the mechanisms underlying these therapies. It is well established that the combination of MEKis and BRAFis improves progression-free survival and overall survival in patients with *BRAF*-mutated melanoma. This benefit is largely attributed to MEKis' ability to overcome molecular resistance mechanisms that limit the efficacy of BRAFis alone.⁶




Figure 1. Disease progression on CT scan and PET scan after 55 cycles with immunotherapy (nivolumab). Evidence on CT scan (July 2018) of clear progressive disease (PD) localized to the left retroperitoneal and supraclavicular lymph node (upper figures); confirmed lymph node PD on CT-PET scan (lower figures).




Figure 2. Complete response after dabrafenib (BRAFi) and trametinib (MEKi) treatment. CT and PET scans (July 2018) before starting targeted therapy showed PD at the left retroperitoneal and supraclavicular lymph node (left figure); CT and PET scans (March 2019) during target therapy (dabrafenib and trametinib) showed a complete response, minimal accumulation of tracer at the left upper paratracheal lymph node, and a significant reduction in size. Non-fixation of tracer at pleuroparenchymal thickening reported in the left paravertebral region on the 2018 CT scan (right figure).




Figure 3. Diffuse maculopapular rash occurrence in lower and upper limbs post-dabrafenib and trametinib therapy.

BRAFis have been shown to modulate the tumor microenvironment, enhancing immunotherapy by increasing antigen-presenting activity, as well as by reducing tumor secretion of immunosuppressive cytokines and increasing T-cell recognition of tumor antigens, thereby enhancing effector immune cell migration to the tumor.⁷ On the other hand, MEKi may enhance the anti-tumor effects in melanoma cells and decrease the toxicity associated with BRAFi treatment due to their ability to suppress the mitogen-activated protein kinase (MAPK) signaling pathway regardless of *BRAF* mutation.⁸

Similar to the action of BRAFis, MEKis also increase CD8⁺ cell response in the tumor, protecting tumor-infiltrating cells from death caused by chronic T-cell receptor stimulation, preserving their cytotoxic activity, and upregulating tumor antigen expression and maintenance.⁹ When administered in conjunction, MEKis could balance the potential overreaction of effector cells and enhance the tumor microenvironment by targeting cytokine production and immunosuppressive cell populations within it.¹⁰ This has been demonstrated in preclinical and clinical studies, where the alteration of the microenvironment was found to modulate the activity of immune cell activation involved in immune-related adverse reaction development.¹¹ It is well known that although there are significant results from treatment with BRAF/MEKis, there are a number of toxicities that can occur during treatment, some of which can be severe. Among these, the most frequently observed include adverse events of a cutaneous, cardiovascular, and ocular nature, as well as asthenia, pyrexia, and arthralgia.¹²⁻¹⁴

BRAFis and MEKis, when administered prior to or simultaneously with immunotherapy, may transiently modify the tumor microenvironment to enhance immunotherapy sensitivity.¹⁵

Observations reported in this medical case confirm those of other previously published case reports, according to which patients who have received ICI therapy may develop significant toxicities when switching to targeted therapy, with skin manifestations being the most common.¹⁶ However, immunotherapy also seems to have an impact on the severity of some toxicities, notably on rash severity.

In current treatment regimens, immunotherapy failure is often succeeded by targeted therapy as a second-line administration. In relation to this use, it has been suggested that there is a relationship between skin toxicity severity and prior immunotherapy administration as a single treatment regimen.¹⁷ When target therapy treatment with BRAF and MEK inhibitors follows immunotherapy, because of their effect on modulating the tumor microenvironment, an immune-mediated response or toxicity may occur several months after immunotherapy administration.¹⁸

This occurs because it is suspected that immunotherapy may have permanently inhibited the regulatory pathways of the immune system by promoting T-cell effector activation and thus leading to a hypersensitivity reaction when the target therapy is introduced.¹⁹

However, while there is a risk of toxicity, there are proven benefits to administering immunotherapy and targeted therapy regimens, as it appears that immune response activation combined with oncological signaling blocking may result in a more durable response in patients eligible for this treatment option.²⁰

In our clinical case, significant cutaneous and ocular toxicities occurred, necessitating treatment interruption. However, as previously discussed, combining these treatments can provide a longer-lasting response, as demonstrated in our case, where a complete response was maintained for 5 years. The hypothesis for this significant response may stem from a dual mechanism of immune system reactivation; specifically, it is plausible that

following the conclusion of immunotherapy and the initiation of targeted therapy, a synergistic response occurred due to the combined effects of targeted therapy and the residual effects of immunotherapy. This would therefore explain both the increase in toxicity and the long-term complete response.

In this regard, our medical case adds new insights by documenting both skin and ocular toxicities, suggesting that prior exposure to ICIs may predispose patients to a broader spectrum or heightened severity of adverse effects when transitioning to targeted therapy. On the one hand, this highlights the importance of careful monitoring and personalized treatment approaches, as combining these treatments may yield significant results in terms of long-term disease response.

Conclusions

In current treatment regimens beyond clinical trials, targeted therapy is often used as post-first-line treatment for patients who have already received immunotherapy.

It may be useful to investigate the potential impact of prior immunotherapy duration, as well as whether there is a relationship between the timing of immunotherapy discontinuation and the onset of targeted therapy, and how this timing may influence not only the severity of observed toxicities but also the immune response that may be achieved against the tumor.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019;69:7-34.
2. Shah V, Panchal V, Shah A, et al. Immune checkpoint inhibitors in metastatic melanoma therapy (Review). *Med Int (Lond)* 2024;4:13.
3. Moreira A, Heinzerling L, Bhardwaj N, Friedlander P. Current Melanoma Treatments: Where Do We Stand? *Cancers (Basel)* 2021;13:221.
4. Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2018;19:603-15.
5. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. *Ther Adv Med Oncol* 2015;7:122-36.
6. Kakadia S, Yarlagadda N, Awad R, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. *Onco Targets Ther* 2018;11:7095-07.
7. Koya RC, Mok S, Otte N, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. *Cancer Res* 2012;72:3928-37.
8. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *N Engl J Med* 2012;366:207-15.
9. Pulluri B, Kumar A, Shaheen M, et al. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. *Pharmacol Res* 2017;123:95-102.
10. Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. *J Clin Oncol*

- 2014;32:2248-54.
11. Morgese F, Cognigni V, Scortichini L, et al. Potential immune-related adverse events during dabrafenib and trametinib treatment: A case series of patients with BRAF V600E melanoma. *Mol Clin Oncol* 2022;18:2.
 12. Livingstone E, Zimmer L, Vaubel J, Schadendorf D. BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. *Chin Clin Oncol* 2014;3:29.
 13. Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. *Br J Dermatol* 2012;167:987-94.
 14. Renouf DJ, Velazquez-Martin JP, Simpson R, et al. Ocular toxicity of targeted therapies. *J Clin Oncol* 2012;30:3277-86.
 15. Ziogas DC, Konstantinou F, Bouros S, et al. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. *Am J Clin Dermatol* 2021;22:301-14.
 16. Grogan N, Swami U, Bossler AD, et al. Toxicities with targeted therapies after immunotherapy in metastatic melanoma. *Melanoma Res* 2018;28:600-4.
 17. Lamiaux M, Scalbert C, Lepasant P, et al. Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. *Melanoma Res* 2018;28:451-7.
 18. Wyluda EJ, Cheng J, Schell TD, et al. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. *Cancer Biol Ther* 2015;16:662-70.
 19. Cooper ZA, Juneja VR, Sage PT, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. *Cancer Immunol Res* 2014;2:643-54.
 20. Hermel DJ, Ott PA. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. *Cancer Metastasis Rev* 2017;36:43-50. Erratum in: *Cancer Metastasis Rev* 2017;36:51.

Received: 28 February 2025; Accepted: 17 May 2025.

Contributions: Carlotta Bertolina: conceptualization, design, literature search, writing – original draft, writing – review & editing; Marinella Bertolotti: writing – review & editing, supervision; Claudia Leporati, Antonina Maria De Angelis, Sara Delfanti, Luigi Cerbone, Marco Ghiglione: data curation, writing – review & editing; Federica Grosso: conceptualization, design, data curation, writing – review & editing, supervision. All authors reviewed and contributed to the final full text, have approved the submitted version of the manuscript, and agreed to be accountable for any part of the work.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: no ethical committee approval was required for this case report by the Department, because this article does not contain any studies with human participants or animals. Informed consent was obtained from the patient included in this study.

Consent for publication: the patient in this manuscript has given written informed consent for the publication of their case details.

Availability of data and materials: data sharing does not apply to this article, as no new data were created or analyzed in this study.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).